PRODUCT Properties
| Boiling point: | 538.1±45.0 °C(Predicted) |
| Density | 1.086±0.06 g/cm3(Predicted) |
| storage temp. | −20°C |
| pka | 4.75±0.10(Predicted) |
Description and Uses
13,14-dihydro-15-keto Prostaglandin E2 (13,14-dihydro-15-keto PGE2) is a metabolite of PGE2 and the primary PGE2 metabolite in plasma. It is formed from PGE2 via a 15-keto PGE2 intermediate by 15-oxo-PG Δ13 reductase. Unlike PGE2, 13,14-dihydro-15-keto PGE2 does not bind effectively to the PGE2 receptors EP2 and EP4 expressed in CHO cells (Kis = 12 and 57 μM, respectively) or induce adenylate cyclase activity in the same cells (EC50s = >18 and >38 μM, respectively). Levels of 13,14-dihydro-15-keto PGE2 are increased in the plasma of women in the third trimester of pregnancy and in women during and immediately after labor and delivery. Levels of 13,14-dihydro-15-keto PGE2 levels are decreased in tumor tissue compared to adjacent non-cancerous tissue isolated from patients with non-small cell lung cancer (NSCLC).
13,14-Dihydro-15-ketoPGE2 is a primary metabolite of PGE2 in plasma.
Safety
| Symbol(GHS) |   GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302-H312-H315-H319-H332-H335-H351 |
| Precautionary statements | P261-P280-P305+P351+P338 |
| Hazard Codes | F,Xn,Xi |
| Risk Statements | 11-20/21/22-36/37/38-67-66-36 |
| Safety Statements | 16-26-36 |
| RIDADR | UN 1231 3/PG 2 |
| WGK Germany | 3 |
